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Background: Bloodstream infections with antibiotic-resistant Pseudomonas aeruginosa are common and
increasingly difficult to treat. Pyocins are naturally occurring protein antibiotics produced by P. aeruginosa that
have potential for human use.
Objectives: To determine if pyocin treatment is effective in a murine model of sepsis with P. aeruginosa.
Methods: Recombinant pyocins S5 and AP41 were purified and tested for efficacy in a Galleria mellonella infec-
tion model and a murine model of P. aeruginosa sepsis.
Results: Both pyocins produced no adverse effects when injected alone into mice and showed good in vitro
antipseudomonal activity. In an invertebrate model of sepsis using G. mellonella, both pyocins significantly pro-
longed survival from 1/10 (10%) survival in controls to 80%–100% survival among groups of 10 pyocin-treated
larvae. Following injection into mice, both showed extensive distribution into different organs. When adminis-
tered 5 h after infection, pyocin S5 significantly increased survival from 33% (2/6) to 83% (5/6) in a murine model
of sepsis (difference significant by log-rank test, P < 0.05).
Conclusions: Pyocins S5 and AP41 show in vivo biological activity and can improve survival in two models of
P. aeruginosa infection. They hold promise as novel antimicrobial agents for treatment of MDR infections with
this microbe.
Introduction
Pseudomonas aeruginosa is a leading cause of severe hospital-
acquired infections, such as ventilator-associated pneumonia,
burn wound infections and nosocomial bloodstream infections
(BSI). P. aeruginosa accounts for 4% of all hospital-acquired BSI
cases and has a very high (>30%) mortality rate, as well as high
healthcare costs.1–7 In addition, because of P. aeruginosa’s limited
susceptibility to antibiotics and the frequent emergence of resist-
ance during therapy, P. aeruginosa infections are difficult to
treat.8,9 In common with many bacterial pathogens, there is an
increasing prevalence of MDR strains, leading to the classification
of P. aeruginosa as critical on the WHO list of antibiotic-resistant
priority pathogens.10
A potential alternative therapeutic strategy to treat MDR is the
use of the highly potent and narrow-spectrum bacteriocins as
protein antibiotics.11 Bacteria produce these very diverse and wide-
spread proteins during intraspecies competition, where they kill
only bacteria closely related to the producing strain.12,13
Bacteriocins from P. aeruginosa can be classified into different
categories, with the most abundant S-type pyocins resembling
colicins from Escherichia coli.13,14 These multi-domain proteins
share a similar structural organization (including a receptor binding
domain, a translocation domain and a cytotoxic domain) and are
able to efficiently cross the Gram-negative outer membrane
through parasitization of nutrient uptake pathways.15–21 For pyo-
cin S5, initial binding to the cell surface is mediated by the common
polysaccharide antigen and translocation across the outer mem-
brane occurs via the TonB-dependent transporter FptA, which
normally functions in ferripyochelin uptake.15,16 The mechanism
of pyocin AP41 uptake is poorly understood. The cytotoxic activity
of pyocins generally takes the form of a nuclease activity targeting
DNA (such as pyocin AP41), tRNA or rRNA, a pore-forming activity
targeting the cytoplasmic membrane (pyocin S5) or an enzymatic
activity targeting peptidoglycan synthesis.22
The potency and specificity of pyocins makes them potential
candidates for the treatment of P. aeruginosa infection. We previ-
ously demonstrated pyocin S5 and AP41 efficacy for the treatment
of acute pneumonia in a murine model.23 Here we show that
pyocin S5 and pyocin AP41 delivered directly to the blood retain
their bactericidal activity in vivo and display efficacy against a clin-
ical strain of P. aeruginosa in a murine sepsis model of infection.
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Mice provide a good model of human sepsis, displaying many of
the same pathological and immunological features following bac-
terial inoculation.24 Additionally, we tested the efficacy of pyocins
in treating a high-level antibiotic-resistant infection using a Galleria
mellonella systemic infection model that has been widely used in
studies of bacterial infection and antibiotic efficacy,25,26 highlight-
ing their potential as therapeutics in a world of increasing
antimicrobial resistance.
Materials and methods
Bacterial strains, plasmids and growth conditions
The plasmid pETPyoAP41, which encodes the genes for pyocin AP41 and
the C-terminally His6-tagged immunity protein ImAP41 was used for ex-
pression of the pyocin AP41–ImAP41 complex as previously described.23
pPyoS5 was used for the expression of pyocin S5 (with no affinity tag). This
plasmid was constructed by ATUM (Newark, CA, USA) and encodes the
pyocin S5 gene, optimized for expression in E. coli in the vector pJ404.
P. aeruginosa strain P7 is a clinical mucoid strain isolated from a CF pa-
tient.23 E. coli strains were cultured at 37C in LB broth or LB agar supple-
mented with the appropriate antibiotics. Kanamycin and ampicillin were
used at 50 and 100 mg/L, respectively. P. aeruginosa strains were cultured
under agitation at 37C in LB broth or LB agar. Methods for the purification
of pyocins and the generation of antibodies are available as Supplementary
data at JAC Online.
Isolation of a high-level ciprofloxacin-resistant mutant
P. aeruginosa strain P7 was grown until OD600 = 0.6. Ten times serial dilu-
tions of this culture were then plated on LB agar plates supplemented with
1 mg/L ciprofloxacin (Sigma) and the plates incubated overnight at 37C.
Isolated colonies were then subjected to phenotypic characterization using
an overlay spot susceptibility assay and the MIC was determined using
standard methods (see below).
Antibiotic susceptibility assays: MIC
The MIC of antibiotic required to inhibit the visible growth of P. aeruginosa
isolates was determined using a standard method.27 The MIC assay was
carried out using serial dilutions in a 96-well plate with 2-fold dilutions.
G. mellonella larvae infection model
G. mellonella larvae were obtained from Livefood UK, kept in darkness at
room temperature and were used up to 1 week following arrival. Healthy
larvae with no melanization were used for all experiments. P. aeruginosa
was grown under agitation in LB broth at 37C to an OD600 = 0.6. Cells were
then washed twice in sterile PBS and diluted to the desired inoculum in PBS.
Inocula were serially diluted and plated on LB agar plates just before ad-
ministration for cfu counting. Using the approaches outlined in Bell et al.,28
for a survival proportion of 0.8 in a treated group and 0.2 in the control
group, at a power of 95% with a significance level set at 0.01, groups of be-
tween 9 and 10 larvae would be required. Groups of 10 larvae were injected
with 10 lL of bacterial suspension in the haemocoel via the last right pro-
limb. Following challenge, larvae were placed in an incubator at 37C.
Larvae were treated 3 h post-infection by injection of 10lL of BSA, pyocin or
ciprofloxacin in PBS at various concentrations in the haemocoel via the last
left pro-limb. Survival was followed for 48 h; larvae were considered dead
when unresponsive to touch. For each experiment, groups of uninfected lar-
vae (n = 10) were injected with PBS, BSA, pyocin or antibiotics as a negative
control. No deaths were recorded for these control groups. Statistical ana-
lysis of Kaplan–Meier survival curves of each group of larvae was performed
using the log-rank (Mantel–Cox) test.
Stability and clearance of pyocins in vivo
LPS-free and sterile filtered pyocin S5 or pyocin AP41 in PBS were injected IV
in the tail vein at a concentration of 1 mg/mL in 8–10-week-old female
BALB/c mice (ordered from Charles River and left to acclimatize 1 week be-
fore use). For each timepoint, two mice were injected per experiment and
each experiment was done at least two times. The mice were randomly
allocated to each group. Each mouse was marked with a marker on the
tail to keep track on the order they were injected, allowing for precise
timings. Mice were culled by exposure to CO2 at different timepoints fol-
lowing the injection (earliest 10 min, latest 33 h). Blood was obtained
via cardiac puncture immediately following CO2 asphyxiation and
organs were sampled. The blood was left to coagulate for 1 h at room
temperature before being centrifuged for 10 min at 3000 rpm to obtain
the serum. Treatment of organs was as follows: PBS supplemented with
protease inhibitor [1 tablet of cOmplete protease inhibitor (Roche) in
35 mL of PBS] was added to the frozen organs (volume depending on
the weight of the organ) before homogenization using a handheld hom-
ogenizer (Omni). Homogenized organs were then centrifuged at 4C for
20 min at 13 000 rpm and supernatant stored with the sera at #80C
until analysis by pyocin susceptibility assay and immunoblots and
ELISA. Protocols for pyocin quantification by ELISA and immunoblots
and cytokine quantification are available as Supplementary data at
JAC Online.
Murine sepsis model
Using the approaches outlined in Bell et al.,28 for a survival proportion of 0.8
in a treated group and 0.2 in the control group, at a power of 90% with a
significance level set at 0.05, groups of between 5 and 7 mice would be
required. Female BALB/c mice (7 weeks old; weight range 15–20 g) were
obtained from Charles River and randomly allocated to separate cages
(M2-type from North Kent Plastics, UK) containing aspen woodchip bedding
with a maximum of six mice per cage. Mice were left to acclimatize in the
animal unit under a 12:12 h light: dark cycle, with lights on at 7am, for
1 week before use. Groups of six animals were formed randomly prior to the
experiment and were infected by IV injection in the tail vein with a lethal
dose of exponentially growing P. aeruginosa (2%107 cfu). Infections always
took place at the same time of the day (late mornings) to avoid circadian-
rhythm variations. During the experiment, mice had unlimited access to
soft baby food and water. Five hours post-infection, mice were treated with
LPS-free, sterile filtered BSA or pyocins by IV injection. Clinical health was
then monitored for up to 1 week and mice culled by exposure to CO2 when
reaching the endpoint either when the clinical score set as the threshold
(severity score = 7; Table S1, available as Supplementary data at JAC
Online) was reached or at the predefined endpoint of the experiment.
Blood (with or without heparin) and organs were then collected. Statistical
analysis of Kaplan–Meier survival curves of each group of mice was per-
formed using the log-rank (Mantel–Cox) test. For cfu counts, blood was seri-
ally diluted and plated immediately on LB agar. Organs were homogenized
in PBS using a handheld homogenizer (Omni) and plated after serial
dilutions. Statistical analysis of cfu counts was performed using the
Kruskal–Wallis test followed by Dunn’s multiple comparisons test. Serum
was stored at#80C until analysis.
Ethics
All animal experiments were performed in accordance with the UK Animals
(Scientific Procedures) Act, authorized under a UK Home Office License, and
all procedures were approved by the animal project review committee
of the University of Glasgow. The project license number assigned by
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Results
Pyocins S5 and AP41 are bactericidal in different
conditions in vitro
First, we determined the ability of pyocins S5 and AP41 to kill
P. aeruginosa strains under different conditions in vitro. The pyocin
susceptibility spot assay showed that the P7 clinical isolate of
P. aeruginosa was susceptible to both S5 and AP41, with S5 being
more potent [minimum effective dose (MED) = 0.1 ng] than AP41
(MED = 2 ng) (Figure 1a). In LB liquid culture, both pyocins had bac-
tericidal activity, causing a sharp decrease in cfu counts after
30 min of incubation with S5 and after 1 h of incubation with AP41
(Figure 1b). When a combination of both pyocins was used, a com-
bination of both phenotypes was observed, with a quick but stable
decrease in cfu counts over time (Figure 1b). As pore-forming pyo-
cin S5 has been shown to use the ferripyochelin receptor FptA,16
the activity of both pyocins was tested in LB supplemented with
the iron chelator 2.2’-bipyridyl at a final concentration of 2 mM. As
expected, the addition of 2.2’ bipyridyl significantly increased the
bactericidal activity of S5 (Figure 1c). However, the addition of the
iron chelator had no effect on AP41 activity, suggesting that its un-
known receptor is unlikely to be involved in iron uptake. To deter-
mine if pyocins retain their bactericidal activity in blood, bacterial
counts were followed during incubation with recombinant pyocins
in LB supplemented with 50% fresh murine blood (Figure 1c).
The presence of blood increased pyocin S5 activity, with a 10-fold
decrease in cfu numbers compared with incubation in LB alone.
Incubation with AP41 in 50% fresh blood decreased its antimicro-
bial activity; however, this decrease was not significant (Figure 1c).
These results show that both pyocins retain their activity in blood.
Pyocins S5 and AP41 are able to treat lethal
P. aeruginosa infection in G. mellonella larvae
To determine if pyocins AP41 and S5 were able to treat a lethal
systemic infection in vivo, G. mellonella larvae were infected
with 5%103 cfu of P. aeruginosa clinical isolate P7 and treated 3 h
following infection with different doses of pyocins. Larvae were
monitored and survival assessed 24 h post-infection (Figure 2a).
While most untreated larvae were dead by 24 h post-infection, we
observed 80% to 100% survival of larvae treated with either S5
(10 ng to 10 lg) or AP41 (100 ng to 10 lg), showing the effective-
ness of both pyocins to protect against a lethal P. aeruginosa infec-
tion. At the lowest treatment dose tested, S5 was able to rescue
larvae survival, but there was no increase in survival compared
with the untreated larvae when using AP41 (Figure 2a). A separate
experiment, extending to 5 days post-infection, showed that,
following S5 treatment, survival decreased over time, even at the
highest treatment dose (Figure 2b).
Pyocin S5 is able to treat an antibiotic-resistant
P. aeruginosa infection in the Galleria larvae model
In order to test the potency of pyocin S5 to treat an infection
caused by a high-level antibiotic-resistant strain of P. aeruginosa,
we generated a high-level ciprofloxacin-resistant mutant
(P7ciproR!) derived from the clinical isolate P7. The initial P7 isolate
is already resistant to ciprofloxacin (MIC = 2 mg/L); the derived
high-level resistant mutant had an MIC of 16 mg/L. In vitro, this
mutant retained its susceptibility to pyocin S5 (Figure 3a). The effi-
cacy of S5 against the P7ciproR! mutant was assessed in vivo using
the Galleria larvae model (Figure 3b and c and Figure S1). As
expected, while survival of larvae infected with the WT P7 strain
was increased by treatment with ciprofloxacin (10 lg, 80% survival
48 h post-infection), the same treatment was only able to delay
the deaths of the larvae infected with the P7ciproR! mutant, with
Figure 1. Purified pyocins S5 and AP41 are active in vitro. (a) Spot tests
to determine the activity of pyocins S5 and AP41 against P. aeruginosa
strain P7; 5 lL of a range of concentrations of pyocin S5/AP41 was
spotted on a growing lawn of P. aeruginosa. The presence of clear zones
indicates pyocin activity. (b) Bacterial counts over time of P. aeruginosa
incubated in LB medium supplemented with PBS (control) or 10 mg/L S5,
AP41 or S5!AP41. (c) Bacterial counts of P. aeruginosa after 4 h of incu-
bation with PBS, S5, AP41 or S5!AP41 (10 mg/L) in different conditions:
LB, LB!200 nM 2.2’ bipyridyl or LB!fresh whole murine blood (50%).
Bars represent the average cfu counts in cfu/mL from three experiments.
Error bars represent the SD and asterisks indicate significant differences,
as assessed by one-way ANOVA (*P < 0.05).
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100% mortality observed 27 h post-infection. S5 was able to res-
cue the larvae infected with the WT P7 strain or P7ciproR! mutant
equally effectively (90% survival 48 h post-infection for both).
Pyocin dissemination, degradation and activity in mice
To begin exploring the utility of pyocins in treating P. aeruginosa
blood infections, we first investigated their distribution, clearance
and stability in vivo. High doses of AP41 or S5 (200lg) were
injected IV into mice and the concentrations of AP41 and S5 in
serum over time were determined by ELISA using polyclonal
specific AP41 or S5 antibodies, respectively (Figure 4a). The serum
concentration of S5 decreased sharply almost immediately
following injection, being detectable in the serum only up to 1 h
post-injection. By contrast, the serum concentration of AP41 only
slightly decreased over time. Dissemination of S5 and AP41 from
the blood to different organs was then determined by western blot
(Figure 4b). Pyocin S5 was detected up to 1 h following injection in
serum, confirming the ELISA results, as well as in the spleen, lungs
and liver, showing good distribution of the pyocin. Pyocin AP41 was
detected up to 24 h post-injection in serum, spleen, lungs and liver,
showing good distribution and stability. Finally, we tested the kill-
ing activity against P. aeruginosa of both pyocins from the same
samples (Figure 4c). As expected, zones of inhibition were detected
up to 1 h post-injection in serum, lungs and spleen of S5-treated
mice and up to 24 h in serum and lungs of AP41-treated mice. The
antibacterial activity demonstrated using the susceptibility assay
correlates well with results from both western blot and ELISA tech-
niques, other than a lack of bactericidal activity in the spleens of
AP41-treated mice. To determine if injection of pyocins on their
own induces a pro- or anti-inflammatory response in non-infected
mice when injected IV, we quantified levels of pro-inflammatory
(IL-1b and TNF-A) and anti-inflammatory (IL-10) cytokines in
serum samples from S5- and AP41-treated mice and compared
these with the levels observed in non-injected mice. Neither pyocin
S5 nor pyocin AP41 induced production of these cytokines, with
levels in treated animals remaining very similar to those of control
mice (Figure S2).
Pyocins S5 and AP41 improve survival of septic mice
To determine if pyocins S5 and AP41 are able to improve survival
rates of septic mice when administered post-infection, 7-week-old
mice were infected by IV injection of a lethal dose of strain P7 and
treated with IV injection of 2 lg of pyocin S5 or AP41 at 5 h post-in-
fection. Representative experiments are shown in Figure 5. Pyocins
S5 and AP41 were able to increase survival in this model from 33%
to 83% and 67%, respectively (Figure 5a); this is significant for S5,
but not AP41 (log-rank test, P < 0.05). A second injection of 2 lg of
S5 did not improve the survival rate; in addition, the use of a cock-
tail of S5 and AP41 did not improve the survival rate. To determine
if increasing the concentration would result in increased survival of
infected mice, different doses of pyocin S5 were used (200, 20 and
2 lg) and the mice monitored for 72 h. Treatment with 2, 20 or
200 lg of pyocin S5 had a very similar effect on survival (Figure 5b).
Although there was an increase in survival for the mice treated
with pyocin S5 or AP41, they still displayed signs of infection.
Following infection, mice were monitored regularly and a health
score given to each of them using a scoring system for disease se-
verity (Table S1 and Figure 5c). The onset of the disease for sham-
treated mice occurred between 18 and 24 h post-infection. At 18 h
post-infection, mice were given an average score of 4.6, 3.0 and
3.6 for sham-treated, S5-treated and AP41-treated mice, respect-
ively; a significant reduction at that timepoint for pyocin-treated
mice. As most sham-treated mice did not survive beyond the 18 h
post-infection timepoint, no clinical scores were included for that
group after this timepoint. Comparison of the health scores of S5-
and AP41-treated mice 24 and 30 h post-infection shows signifi-
cantly lower health scores and a more rapid recovery of S5-treated
mice. The mice were monitored for up to 7 days following infection
and, once completely recovered, no relapse was observed and
there were no delayed murine deaths. Measurement of the con-
centrations of serum pro- and anti-inflammatory cytokines (IL-1b,
Figure 2. Purified pyocins S5 and AP41 are able to treat P. aeruginosa-infected G. mellonella larvae. Experiments were performed with 10 larvae per
group per experiment. (a) Twenty-four hour survival of larvae infected with P. aeruginosa strain P7 and treated 3 h post-infection with BSA, S5 or
AP41. Bars represent the mean survival from two experiments (n = 10 larvae per group per experiment). Error bars represent the SD and asterisks indi-
cate significant differences relative to larvae treated with PBS, as assessed by one-way ANOVA (ns, non-significant; ****P < 0.0001; ***P < 0.001). (b)
Kaplan–Meier survival curves of larvae infected with P. aeruginosa strain P7 and treated 3 h post-infection with different doses of S5. Survival curves
are representative of two distinct experiments; n = 10 larvae per group per experiment. Asterisks indicate significant differences relative to larvae











 user on 07 July 2021
IFN-c, TNF-A and IL-10) quantified for each mouse before
infection, after infection and after pyocin injection showed there
was no significant difference in cytokine levels following treatment
of infected mice with BSA, pyocin S5 or pyocin AP41 (Figure S3).
To determine if pyocins S5 and AP41 are able to reduce bacter-
ial load in mice following infection, groups of six mice were culled
6, 12 and 19 h post-infection and bacterial counts in blood, liver,
lungs and spleen from treated mice were compared with those of
sham-treated mice (Figure 6). In these experiments, S5 significant-
ly reduced bacterial load in the blood at 6 and 12 h post-infection.
Differences between groups were tested by the Kruskal–Wallis test
and were significant (P < 0.05) and individual timepoint differences
Figure 3. Purified pyocin S5 is active against ciprofloxacin-resistant
P. aeruginosa in vitro and in vivo. (a) Spot tests to determine the activity
of ciprofloxacin and pyocin S5 against P. aeruginosa strain P7 and a P7-
derived ciprofloxacin-resistant mutant. Three microlitres of a range of
concentrations of ciprofloxacin (3 lg to 23 ng of ciprofloxacin, 2% dilu-
tions) and pyocin S5 (3 lg to 0.3 pg of pyocin S5, 10% dilutions) was spot-
ted on a growing lawn of P. aeruginosa. The presence of clear zones
indicates pyocin or antibiotic activity. (b and c) Kaplan–Meier survival
curves of larvae infected with the WT P. aeruginosa P7 strain (b) or the
P7-derived ciprofloxacin-resistant mutant (P7ciproR!) (c) (n = 10 per
group) treated 3 h post-infection with ciprofloxacin (10 lg) or pyocin S5
(5 lg). Control uninfected larvae (n = 10 per group) were injected with
PBS. Groups of uninfected larvae (n = 10 per group) were also injected
with ciprofloxacin (10 lg) or pyocin S5 (5 lg) and all survived, but are not
represented here. Survival curves are representative of two distinct
experiments. Asterisks indicate significant differences relative to larvae
treated with PBS, as assessed by the log-rank (Mantel–Cox) test
(*P < 0.05; ****P < 0.0001).
Figure 4. Pyocins S5 and AP41 have different dissemination and
clearance profiles in mice. (a) Serum concentration of S5 and AP41
determined by ELISA following IV injection of 200 lg of pyocins in mice.
Results represent the mean from three independent experiments, two
mice per timepoint and per experiment. Error bars represent the SD.
(b) Detection of pyocins S5 and AP41 in serum and organ homogenates
at different timepoints (10 min, 30 min, 1 h, 3 h, 6 h, 9 h and 24 h) follow-
ing injection using S5- or AP41-specific affinity-purified antibodies.
Positive control (!) = 1.25 ng of purified S5 or AP41. Negative control
(-) = corresponding homogenized organ from a mouse that did not re-
ceive injections of S5 or AP41. (c) Detection of pyocin S5 or AP41 activity
in serum or homogenized organs at different timepoints following IV in-
jection. Five microlitres of homogenized organ or serum was spotted on
a growing lawn of P. aeruginosa strain P7. The presence of clear zones
indicates pyocin activity.
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were assessed by Dunn’s multiple comparison test and were sig-
nificant as shown (P < 0.05). However, the reduction in bacterial
numbers in the blood of AP41-treated mice was not significant
(Figure 6a). As both bacteria and pyocins will disseminate from the
blood to organs, we also determined bacterial load in the organs of
untreated and treated mice. There was no significant reduction in
bacterial numbers in the liver and lungs of pyocin-treated mice
(Figure 6b and c). In the spleen, we observed a significant decrease
in cfu counts 19 h post-infection for AP41-treated mice (Figure 6d).
No bacteria were found in the blood of mice that recovered from
infection after being treated with 2 lg of S5 (n = 6, t = 72 h post-in-
fection; n = 5, t = 168 h post-infection) or with 2 lg of AP41 (n = 6,
t = 72 h post-infection; n = 5, t = 168 h post-infection). To determine
if pyocin tolerance was acquired following IV treatment of septic
mice, cfu recovered from mice at different timepoints following in-
fection were tested for pyocin susceptibility (n = 119; Table S2). No
difference in susceptibility to pyocin S5 or AP41 was observed in
colonies recovered from mice compared with that of the original
P7 strain.
Discussion
In this study, single injections of two P. aeruginosa-specific pyocins
are shown to improve the survival of septic mice. When injected
directly in the blood, pyocins do not provoke an immune reaction,
remain stable and retain their activity for a minimum of 1 h for S5
and 24 h for AP41. We demonstrate that both pyocins are able to
disseminate into the liver, the spleen and the heart, where they
are active. Surprisingly, while AP41 is found to remain stable
and active in the blood and organs for a longer period in vivo, and
found to be more efficient for colony-count reduction in vitro, it is
actually less efficient as treatment in a murine model of sepsis.
Additionally, we saw no significant reduction in cfu counts in
the blood of infected mice following treatment with AP41.
Interestingly, the difference in efficacy of treatment with S5 and
AP41 in infected mice was also observed in infected larvae, further
validating the use of G. mellonella larvae as a bridge between
in vitro assay and murine infection models. These observations
could be due to a mechanistic difference between AP41 and S5 kill-
ing or an interaction of AP41 with host proteins, decreasing its ac-
tivity in vivo against P. aeruginosa. Further studies would be
necessary to test these different hypotheses.
A single injection of pyocin is not sufficient to produce a 100%
survival rate, although the bacteria recovered from animals follow-
ing infection and treatment were not resistant or tolerant to the
pyocins. It is possible that giving a continuous IV infusion of pyocin
will increase the survival rate, although a second injection of
pyocin S5 at 12 h post-infection did not improve survival compared
with a single injection.
Taken together, our results show that pyocins can act as effect-
ive agents in the animal models of sepsis used in these studies
and further investigations of their potential for use as targeted
therapeutics in P. aeruginosa infections are warranted.
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Figure 5. Pyocins S5 and AP41 improve survival of septic mice. For each
experiment the number of mice per individual treated group was six. (a)
Kaplan–Meier survival curves of mice (n = 6 per group) infected IV with
5.6%107 cfu of P. aeruginosa strain P7 and treated with IV injection 5 h
post-infection with a single injection of 2 lg of BSA, S5 or AP41, with an
injection of a cocktail of S5!AP41 (2 lg) or with two injections of 2 lg of
S5 (5 and 11 h post-infection). (b) Kaplan–Meier survival curves of mice
infected IV with 4%107 cfu of P. aeruginosa strain P7 and treated with IV
injection 5 h post-infection with 200 lg (dotted line), 20 lg (dashed line)
or 2 lg (solid line) of S5 or 200 lg of BSA. Survival curves are representa-
tive of at least two independent experiments, n = 6 per group. Asterisks
indicate significant differences relative to mice treated with BSA, as
assessed by the log-rank (Mantel–Cox) test (ns, non-significant;
*P < 0.05). (c) Clinical scores of infected mice at 18, 24 and 30 h post-in-
fection. Data were collected from four different experiments, n = 6 per
group. Asterisks indicate significant differences, as assessed by one-way
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